Adamis Pharmaceuticals Corporation logo

Adamis Pharmaceuticals Corporation Investor Relations Material

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company is focused on developing and commercializing products in the therapeutic areas of allergy, opioid overdose and respiratory disease. The company's product candidate includes Symjepi (previously known as APC-5000), an epinephrine syringe for self-administration by patients for emergency treatment of acute allergic reactions, including anaphylaxis. It is designed to be prefilled and ready to use immediately at the time of need. The Company's sales channels include the Pulmonary Division of Forest Laboratories, Inc., which markets Symjepi to wholesalers exclusively in the U.S

Latest company events

Ticker symbol

ADMP

Country

United States of America

Dig deeper into the Adamis Pharmaceuticals Corporation fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot